GSK vs TRVI: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

GSK is the larger of the two ($96.65B market cap): the incumbent the market prices for continued execution (9.72x forward earnings, beta 0.28). TRVI is the smaller challenger ($1.92B), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, TRVI fits (beta 1.12). If you want the steadier ride, GSK fits (beta 0.28).

GSK vs TRVI: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricGSKTRVIWhat it tells you
Market cap$96.65B$1.92BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E9.72-22.14Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.281.12Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range15% of range35% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book3.856.33How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how GSK and TRVI affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GSK and TRVI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GSK and TRVI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does GSK plc (GSK) do?

GSK plc is a UK-headquartered global biopharma company, one of the largest by revenue, focused on preventing and treating disease through vaccines, specialty medicines, and general medicines. It reorganized in 2022 when it spun off its consumer health arm as Haleon, leaving GSK as a pure biopharma business. Its most durable franchises are vaccines, led by the shingles vaccine Shingrix and the newer RSV vaccine Arexvy, and HIV, which it manages largely through the ViiV Healthcare joint venture with a shift toward long-acting injectable regimens. It also has growing positions in respiratory, immunology and inflammation, and oncology.

Full GSK guide

What does Trevi Therapeutics (TRVI) do?

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough. Haduvio is designed to act on the cough reflex both centrally and peripherally as a kappa-opioid agonist and mu-opioid antagonist (a KAMA mechanism), a different approach from the P2X3 antagonists that most rivals pursue. Trevi is targeting three indications: chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company has no marketed products and generates no product revenue, so it funds itself through equity raises and operates at a net loss, which is typical for a company at this stage.

Full TRVI guide

GSK vs TRVI: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • GSK drivers: Vaccines franchise durability; HIV, long-acting injectables and the 2028 cliff.
  • TRVI drivers: Haduvio Phase 3 in IPF-related chronic cough; Refractory chronic cough expansion.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The central risk is the patent cliff and pipeline dependence: the dolutegravir HIV medicines lose US patent protection from April 2028 (Dovato at the end of 2029), other maturing products face generic and biosimilar competition, and the longer-term case relies on newer launches replacing that revenue, which is never guaranteed in drug development. For TRVI, trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value.

GSK or TRVI: which should you pick?

If the story you believe is GSK's (Vaccines franchise durability), GSK is the more direct way to own it; if it is TRVI's (Haduvio Phase 3 in IPF-related chronic cough), TRVI is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GSK and TRVI guides.

GSK vs TRVI: the full fundamentals

GSK. At under 10 times forward earnings and a 3.8% yield, GSK is priced as a value-and-income pharma name, below several US large-cap peers, after a year in which the ADR gained only about 5% and gave back about 7% over the last three months. Figures mix pounds (company reporting) and dollars (the US ADR), so verify live numbers before relying on them. Analysts expect 2026 EPS of about $4.76 per ADR on roughly £33.8 billion of revenue, rising to about $4.96 in 2027, so the market is pricing in modest growth through the approach of the 2028 HIV patent expiries.

TRVI. As a clinical-stage biotech, Trevi has no product revenue and runs at a net loss, so price-to-earnings does not apply. The roughly $1.9 billion market capitalization, about 6 times book value, reflects expectations for Haduvio's OCEAN and LAKE trials, with roughly $299 million of cash covering a meaningful slice of that value. Analysts expect a loss of about $0.49 per share for 2026 and $0.61 for 2027 as trials run; the average target of about $28 across 11 analysts sits well above the current price.

Headline figures (approximate, November 2026): GSK shows revenue (ttm) ~£33.5 billion, up ~4% year over year in Q3 2026 (~£8.9 billion), operating margin ~31% (gross margin ~74%, net profit margin ~13%), net income (ttm) ~£4.35 billion; trailing EPS ~$2.87 per ADR, latest quarter eps Q3 2026 adjusted ~$1.45 per ADR vs ~$1.33 expected; TRVI shows market cap ~$1.9 billion, share price (nov 20, 2026) ~$13.53, cash and marketable securities (sept 30, 2026) ~$299 million, net loss (ttm) ~$61 million.

The bottom line: GSK vs TRVI

GSK and TRVI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined GSK and TRVI exposure against your real portfolio. It is not an investment adviser.

Wondering how GSK or TRVI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about GSK plc

Ask Walnut's AI anything about GSK and see how it fits what you own.

FAQ

What is the difference between GSK and TRVI?

+

GSK plc is a UK-headquartered global biopharma company, one of the largest by revenue, focused on preventing and treating disease through vaccines, specialty medicines, and general medicines. Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is GSK or TRVI the better stock?

+

Neither is universally better. GSK is the larger incumbent; TRVI is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, GSK or TRVI?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both GSK and TRVI?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of GSK vs TRVI?

+

GSK: The central risk is the patent cliff and pipeline dependence: the dolutegravir HIV medicines lose US patent protection from April 2028 (Dovato at the end of 2029), other maturing products face generic and biosimilar competition, and the longer-term case relies on newer launches replacing that revenue, which is never guaranteed in drug development. GSK has been viewed as having a historically less dynamic pipeline than some rivals, so R&D setbacks or trial failures would weigh heavily, and Nelkarmi's approval is accelerated, so it depends on confirmatory data. Litigation is another overhang, notably the long-running Zantac cases where GSK has been named among defendants, which can create headline and financial uncertainty. As an ADR of a UK company, US investors also carry currency risk between the pound and the dollar, plus exposure to UK and EU drug-pricing policy and US pricing reform. Vaccine demand can be lumpy year to year, and competition from Pfizer, Merck, and AstraZeneca across vaccines, HIV, and oncology is intense. Leverage rose after the Nuvalent purchase: GSK held about £3.0 billion of cash against roughly £23.8 billion of debt at the end of September 2026 (up from about £18.3 billion earlier in the year), with management citing leverage near 1.8 times. Reported earnings also swing with one-off charges (net income was about £435 million in the second quarter of 2026 against £1.54 billion in the third), so trailing P/E can look higher than the underlying business suggests. TRVI: Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Even with a large cash balance, the company burns cash every quarter (the loss grew from about $13.2 million in Q1 2026 to $21.5 million in Q3) and will likely need additional financing before Haduvio could reach the market, and equity raises dilute existing shareholders (the April 2026 offering issued 11.6 million new shares). Timelines can slip, as the LAKE sample size re-estimation did when it moved from late 2026 into early 2027. Because Haduvio is derived from an opioid (nalbuphine), it faces scheduling, safety, and tolerability scrutiny that non-opioid rivals avoid. It also competes with well-capitalized programs from Merck, GSK, Bayer, and others. Insiders have sold some stock (one September 2026 filing showed about $596,000 of sales), and the shares are down about 25% over three months to November 20, 2026, a reminder of how quickly sentiment can swing without new data. Finally, the ~$1.9 billion market value already embeds significant expectations of clinical and regulatory success, so disappointing data could trigger a sharp decline.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GSK or TRVI; figures are approximate and dated (as of November 2026). Verify current data before investing.